Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications

Journal of Clinical Hypertension

Volumn 21, Issue 1, 2019, Pages 4-15

  DiPette, Donald J ^a   Skeete, Jamario ^a,b   Ridley, Emily ^b   Campbell, Norm R C ^c   Lopez Jaramillo, Patricio ^d,e   Kishore, Sandeep P ^f,g   Jaffe, Marc G ^h,i   Coca, Antonio ^j   Townsend, Raymond R ^k   Ordunez, Pedro ^l  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Palmetto Richland Memorial Hospital   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSIDAD DE SANTANDER   (Colombia)

^e School of Engineering Sciences and Industry   (Ecuador)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g Young Professionals Chronic Disease Network   (United States)

^h Vital Strategies   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j UNIVERSITY OF BARCELONA   (Spain)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l PAN AMERICAN HEALTH ORGANIZATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS PERINDOPRIL; AMLODIPINE PLUS RAMIPRIL; AMLODIPINE PLUS TELMISARTAN; AZILSARTAN; AZILSARTAN MEDOXOMIL PLUS CHLORTALIDONE; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CANDESARTAN; CHLORTALIDONE; FOSINOPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; ANTIHYPERTENSIVE AGENT;

AGE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ETHNICITY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; MONOTHERAPY; NOTE; PATIENT EDUCATION; PILL; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; ALGORITHM; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; MALE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 85057237669     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.13426     Document Type: Note

References (55)

1. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
3. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control - global disparities of hypertension prevalence and control a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441-450.
4. Whelton PK, Committee W, Carey RM, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2017;2017(17):735-1097.
5. Williams B, Mancia G, Desormais I. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.
6. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699.
7. Jaffe MG, Frieden TR, Campbell N, et al. Recommended treatment protocols to improve management of hypertension globally: a statement by resolve to save lives and the World Hypertension League (WHL). J Clin Hypertens. 2018;20(5):829-836.
8. Melgarejo JD, Maestre GE, Thijs L, et al. Prevalence, treatment, and control rates of conventional and ambulatory hypertension across 10 populations in 3 continents novelty and significance. Hypertension. 2017;70(1):50-58.
9. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959.
10. Ordunez P, Martinez R, Niebylski ML, Campbell NR. Hypertension prevention and control in Latin America and the Caribbean. J Clin Hypertens. 2015;17(7):499-502.
11. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. Drugs. 2002;62(3):443-462.
12. Turner R, Matthews D, Neil A, Mcelroy H. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
13. Cruickshank JM. Hypertension optimal treatment (HOT) trial. Lancet. 1998;352(9127):573-574.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
15. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation. 2010;122(8):847-849.
16. Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2009-2020.
17. SPRINT Research Group, Wright JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
18. Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506-525.
19. Task Force of the Latin American Society of Hypertension. Guidelines on the management of arterial hypertension and related comorbidities in Latin America. J Hypertens. 2017;35(8):1529-1545.
20. National Clinical Guideline Centre (UK). Hypertension: clinical management of primary hypertension in adults (NICE clinical guideline 127). https://www.ncbi.nlm.nih.gov/books/NBK83274/. Accessed July 2018.
21. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569-588.
22. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr. 2010;2(1):44.
23. Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4(2):119-127.
24. Tung Y-C, Huang Y-C, Wu L-S, Chang C-J, Chu P-H. Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment. J Clin Hypertens. 2017;19(10):983-989.
25. Satsoglou S, Tziomalos K. Fixed-dose combinations: a valuable tool to improve adherence to antihypertensive treatment. J Clin Hypertens. 2018;20(5):908-909.
26. Du L-P, Cheng Z-W, Zhang Y-X, Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens. 2018;20(5):902-907.
27. Hong SH, Wang J, Tang J. Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy. Am J Hypertens. 2013;26(7):879-887.
28. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
29. Angeli F, Reboldi G, Mazzotta G, et al. Fixed-dose combination therapy in hypertension. High Blood Press Cardiovasc Prev. 2012;19(2):51-54.
30. Rabbani A, Alexander GC. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens. 2008;21(5):509-513.
31. Bramlage P, Schmidt S, Sims H. Fixed-dose vs free-dose combinations for the management of hypertension-an analysis of 81 958 patients. J Clin Hypertens. 2018;20(4):705–715.
32. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300.
33. Jaffe MG, Young JD. The kaiser permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens. 2016;18(4):260-261.
34. Patel P, Ordunez P, DiPette D, et al. Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: the standardized hypertension treatment and prevention project. J Clin Hypertens. 2016;18(12):1284-1294.
35. Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Heal. 2017;2(9):e411-e419.
36. Nguyen TA, Knight R, Roughead EE, Brooks G, Mant A. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plan. 2015;30(2):267-280.
37. de L Horst MM, SolerO. [The PAHO strategic fund: a mechanism to facilitate access to medicines]. Rev Panam Salud Publica. 2010;27(1):43-48.
38. Ordunez P, Ramon M, Niebylski M, Campbell NR. Hypertension prevention and control in Latin America and the Caribbean. J Clin Hypertens. 2015;17(7):499-502.
39. WHO. Fixed-Dose Combination Antihypertensives. Geneva, Switzerland: WHO; 2018. https://www.who.int/selection_medicines/committees/expert/22/fixed-dose_combination_antihypertensives/en/. Accessed August 15, 2018.
40. Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011;7:777-787.
41. Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012;18(3):139-146.
42. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-434.
43. Whelton P, David B. Benazepril plus amlodipine or hydrochlorothiazide for hypertension. N Engl J Med. 2009;360(11):1147-1150.
44. Coca A, López-Jaramillo P, Thomopoulos C, Zanchetti A, Latin American Society of Hypertension (LASH). Best antihypertensive strategies to improve blood pressure control in Latin America. J Hypertens. 2018;36(2):208-220.
45. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;(8):CD009096.
46. Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens. 2015;17(3):193-199.
47. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-207.
48. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81(6):796-806.
49. Jadhav U, Wadhwa N. Randomised controlled clinical trials of azilsartan: a systematic review and evidence based perspectives. J Am Soc Hypertens. 2016;10(4):e27-e28.
50. Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Hypertension. 2011;57(4):665-666.
51. Springer K. Chlorthalidone vs. hydrochlorothiazide for treatment of hypertension. Am Fam Physician. 2015;92(11):1015-1016.
52. WHO. HEARTS Technical Package. Geneva, Switzerland: WHO; 2018.
53. Patel P, Ordunez P, Connell K, Lackland D, DiPette D. Standardized hypertension management to reduce cardiovascular disease morbidity and mortality worldwide. South Med J. 2018;111(3):133-136.
54. Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS data brief, no 220. Hyattsville, MD: National Center for Health Statistics; 2015.
55. Frieden TR, Bloomberg MR. Saving an additional 100 million lives. Lancet. 2018;391(10121):709-712.